Chronic Spontaneous Urticaria Market Heats Up as Pharma Companies Race to Address Unmet Needs | DelveInsight
DelveInsight reports the chronic spontaneous urticaria (CSU) market in the 7MM was about $2 billion in 2025, with roughly 4.8 million diagnosed prevalent cases, expected to rise by 2036. The US led in 2025. The report cites emerging therapies including Celldex’s barzolvolimab, Sanofi’s rilzabrutinib, and Jasper’s briquilimab, plus FDA approval of dupilumab for pediatric CSU.
How this was made
The 30-second read
Why it matters
The only clearly time-specific, company-relevant items are (1) an FDA approval expansion for DUPIXENT in pediatric CSU and (2) Nurix’s May 2026 preclinical/Phase 1 translational findings presentation for NX-5948. The rest is largely pipeline/market framing without new numbers.
Market read
Traders may monitor dupilumab label expansion and NX-5948 pipeline momentum, but the article lacks quantitative catalysts to drive large, immediate repricing.
What to watch
No efficacy magnitude, safety profile, uptake assumptions, or competitive positioning metrics are provided; without these, near-term pricing impact is likely muted.
Background
The piece is a DelveInsight market report promotion describing CSU prevalence, market size, and a pipeline of emerging therapies.
Ticker impact
Sanofi’s rilzabrutinib (orally BTK inhibitor) is presented as a first-/best-in-class CSU therapy candidate.
Low likelihood of immediate repricing absent new trial results or FDA action in the article.
The article provides general development descriptions and market context, not a fresh, attributable catalyst for SNY.
Jasper Therapeutics’ briquilimab is described as a Phase Ib/IIa investigational antibody targeting the SCF/CD117 axis for CSU.
Negligible to low near-term impact; any reaction would be speculative without new efficacy/safety data.
No new trial readout, enrollment update, or regulatory milestone for briquilimab is disclosed.
Nurix Therapeutics reports new preclinical and Phase 1 translational findings for bexobrutideg (NX-5948) in May 2026.
Potential modest positive biotech sentiment read-through, but magnitude unclear without effect-size details.
The article states findings were reported/presented, but provides no efficacy/safety numbers or regulatory consequence.
Market effects
Highlights a competitive shift toward targeted biologics and oral small molecules (BTK/JAK/other) in CSU, which can influence biotech sentiment and pipeline expectations.
Emphasizes the US as the largest CSU market in 2025, implying US regulatory/label expansions may drive disproportionate commercial focus.
Frames CSU as a growing 7MM market through 2036, supporting continued global investment in immunology/dermatology pipelines.
Counterpoint
Because this is a market-insight PR with limited quantitative trial/label details, the incremental tradable signal may be smaller than the headline implies.
Key entities
- drugDUPIXENT (dupilumab)
FDA approval is described for children aged 2–11 with chronic spontaneous urticaria.
- drugbexobrutideg (NX-5948)
Nurix reported new preclinical and Phase 1 translational findings for CSU in May 2026.
- drugBarzolvolimab (CDX-0159)
Celldex’s KIT-inhibiting monoclonal antibody is positioned as a CSU candidate.
